查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1400724

口服聚合物製剂的全球市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按适应症、按最终用户、按地区

Oral Macromolecular Formulation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 158 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球口服聚合物药物市场正经历显着成长，预计2024年销售额将达到1,800万美元。预计该市场将维持 7% 的强劲复合年增长率 (CAGR)，到 2031 年底估计估值将达到约 2,800 万美元。

口服药物递送因其优点而成为最理想的途径，包括固体製剂的可能性，例如延长的保质期、持续的分布和增强的免疫反应。

口服聚合物製剂可以减少与注射相关的许多风险，例如针伤、疼痛和针刺伤。美国每年约有 385,000 起医护人员遭受锐器伤害，凸显了更安全替代方案的重要性。由于注射带来的不适，儿科患者对口服製剂的需求尤其高。

口服给药因其非侵入性、患者依从性和易用性而成为最常见的药物传递方法。口服给药对于老年体弱的患者尤其重要，他们可以自行给药而无需帮助。

由于其成本效益，口服聚合物製剂的需求量很大，特别是在低收入地区。专门从事口服聚合物製剂的研究人员和合约製造商致力于透过提供新颖实用的单剂量製剂来简化患者的生活。

全球糖尿病发生率的增加正在推动对口服聚合物製剂的需求，因为糖尿病患者可能需要胰岛素治疗。与静脉注射相比，胰岛素等生物分子的口服製剂具有潜在的优势，静脉注射可能会给患者带来不舒服和挑战。

製药商正在积极探索各种方法来增强生物製剂的口服给药，以克服酵素降解和酸降解。口服聚合物製剂的吸收面临生理障碍，许多聚合物容易被消化酵素快速降解。胃酸碱度也影响药物吸收。

由于技术进步、专利批准增加以及药物传输奈米技术应用的区域研究，美国市场正在不断成长。德国市场预计将继续成长，积极的研发活动集中在新的药物输送系统。

该报告考察了全球口服聚合物药物市场，并提供了市场概况，包括按适应症、最终用户、地区划分的趋势以及进入市场的公司的竞争趋势。

目录

第一章执行摘要

第二章市场概况

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • COVID-19 影响分析
  • 乌克兰与俄罗斯衝突的影响
  • 经济概况
  • PESTLE分析

第三章 2018-2031年全球口服高分子药物市场展望

  • 2018-2031 年全球口服聚合物药物市场前景（按适应症、价值（百万美元））
  • 全球口服聚合物药物市场前景（按最终用户划分），价值（百万美元），2018-2031 年
  • 2018-2031 年全球口服聚合物药物市场前景（按地区、价值（百万美元））

第四章 2018-2031年北美口服高分子药物市场展望

第五章 2018-2031年欧洲口服高分子药物市场前景

第六章 2018-2031年亚太口服高分子药物市场展望

第七章 2018-2031 拉丁美洲口服聚合物药品市场展望

第8章 2018-2031年中东及非洲口服高分子药物市场前景

第9章 竞争格局

  • 按製造商和最终用户划分的热图
  • 2023 年公司市场份额分析
  • 比赛仪表板
  • 公司简介
    • Catalent, Inc
    • Diabetology Ltd
    • UPM Pharmaceuticals

第10章附录

简介目录

The global Oral Macromolecule Formulation Market is experiencing remarkable growth, with revenues reaching US$ 18 million in 2024. Market analysts anticipate a steady Compound Annual Growth Rate (CAGR) of 7%, propelling the market to an estimated valuation of approximately US$ 28 million by the end of 2031.

Oral Delivery: The Preferred Route

Oral drug delivery has emerged as the most desirable route due to its advantages, including the potential for solid formulations with extended shelf life, continuous distribution, and enhanced immune response.

The numerous risks associated with injections, such as needle-related injuries, pain, and needle stick injuries, can be mitigated by oral macromolecule formulations. Approximately 385,000 sharp injuries occur among healthcare workers in the US each year, highlighting the importance of safer alternatives. Pediatric patients, in particular, have a high demand for oral formulations due to the discomfort associated with injections.

Growing Preference for Oral Administration

Oral administration has become the most popular method of drug delivery due to its non-invasiveness, patient compliance, and ease of use. It is especially crucial for elderly and physically fragile individuals, enabling self-administration of medications without the need for assistance.

Affordability and Accessibility

Oral macromolecule formulations are in significant demand, particularly in low-income regions, owing to their cost-effectiveness. Researchers and contract manufacturers specializing in oral macromolecule formulations are dedicated to simplifying patients' lives by offering novel and practical single-unit dosage forms.

Diabetes and Oral Macromolecular Formulations

The global rise in diabetes has driven the demand for oral macromolecular formulations, as diabetic patients may require insulin therapy. The oral formulation of biomolecules like insulin offers potential advantages over intravenous administration, which can be uncomfortable and challenging for patients.

Market Growth Drivers

Introduction of Novel Drug Delivery Systems: Pharmaceutical manufacturers are actively exploring various methods to enhance the oral administration of biologics, aiming to overcome enzymatic and acidic breakdown.

Challenges in Market Growth

Drawbacks and Poor Absorption: The absorption of oral macromolecule formulations faces physiological barriers, and many macromolecules are susceptible to rapid degradation by digestive enzymes. Gastric pH can also impact drug absorption.

Booming U.S. Market

The United States market is experiencing growth due to technological advancements, increased patent approvals, and regional research on nanotechnology applications for drug delivery.

Lucrative Market in Germany

Germany's market is set to advance with growing R&D activities focused on novel drug delivery systems.

China's Research Funding

The National Natural Science Foundation of China has funded various studies on the novel oral delivery of protein and peptide drugs, aligning with the booming market for these pharmaceuticals.

Competitive Landscape

Top pharmaceutical companies are forming strategic alliances with providers of oral macromolecule formulations, and the global market is expected to expand due to the rising demand for pharmaceutical outsourcing.

Key Companies Covered:

  • Catalent, Inc
  • Diabetology Ltd
  • UPM Pharmaceuticals

Market Segmentation

Indication:

  • Inflammatory Bowel Disorder

Crohn's Disease

Ulcerative Colitis

  • Diabetes
  • Others

End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Oral Macromolecular Formulation Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 3.1. Global Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Inflammatory Bowel Disorder
        • 3.1.1.1.1. Crohn's Disease
        • 3.1.1.1.2. Ulcerative Colitis
      • 3.1.1.2. Diabetes
      • 3.1.1.3. Others
  • 3.2. Global Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Biopharmaceutical Companies
      • 3.2.1.2. Academic and Research Institutes
  • 3.3. Global Oral Macromolecular Formulation Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 4.1. North America Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Inflammatory Bowel Disorder
        • 4.1.1.1.1. Crohn's Disease
        • 4.1.1.1.2. Ulcerative Colitis
      • 4.1.1.2. Diabetes
      • 4.1.1.3. Others
  • 4.2. North America Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Biopharmaceutical Companies
      • 4.2.1.2. Academic and Research Institutes
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 4.3.1.2. U.S. Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.3.1.3. Canada Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 4.3.1.4. Canada Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 5.1. Europe Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Inflammatory Bowel Disorder
        • 5.1.1.1.1. Crohn's Disease
        • 5.1.1.1.2. Ulcerative Colitis
      • 5.1.1.2. Diabetes
      • 5.1.1.3. Others
  • 5.2. Europe Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Biopharmaceutical Companies
      • 5.2.1.2. Academic and Research Institutes
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.2. Germany Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.3. U.K. Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.4. U.K. Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.5. France Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.6. France Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.7. Italy Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.8. Italy Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.9. Turkey Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.10. Turkey Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.11. Russia Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.12. Russia Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Inflammatory Bowel Disorder
        • 6.1.1.1.1. Crohn's Disease
        • 6.1.1.1.2. Ulcerative Colitis
      • 6.1.1.2. Diabetes
      • 6.1.1.3. Others
  • 6.2. Asia Pacific Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Biopharmaceutical Companies
      • 6.2.1.2. Academic and Research Institutes
    • 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.2. China Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.3. Japan Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.4. Japan Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.5. South Korea Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.6. South Korea Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.7. India Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.8. India Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 7.1. Latin America Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Inflammatory Bowel Disorder
        • 7.1.1.1.1. Crohn's Disease
        • 7.1.1.1.2. Ulcerative Colitis
      • 7.1.1.2. Diabetes
      • 7.1.1.3. Others
  • 7.2. Latin America Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Biopharmaceutical Companies
      • 7.2.1.2. Academic and Research Institutes
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.2. Brazil Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.3. Mexico Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.4. Mexico Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.5. Argentina Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.6. Argentina Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Inflammatory Bowel Disorder
        • 8.1.1.1.1. Crohn's Disease
        • 8.1.1.1.2. Ulcerative Colitis
      • 8.1.1.2. Diabetes
      • 8.1.1.3. Others
  • 8.2. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Biopharmaceutical Companies
      • 8.2.1.2. Academic and Research Institutes
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.2. GCC Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.3. South Africa Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.4. South Africa Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.5. Egypt Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.6. Egypt Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.7. Nigeria Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.8. Nigeria Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Manufacturer vs by End User Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Catalent, Inc
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Diabetology Ltd
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. UPM Pharmaceuticals
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations